Stock Watch: Vaccines Dominate Second-Quarter Earnings
The Second Half Of 2021 May Be About Different Vaccines
Executive Summary
Pfizer’s earnings were skewed by its coronavirus vaccine for the second quarter running while GSK’s vaccine sales were helped by the catch-up on pediatric immunization schedules. Sales of influenza vaccines may come to the fore in the second half.